Stocks · News reference
AstraZeneca is scheduled to report its third-quarter 2026 financial results, with analysts projecting revenue of $15.99 billion and a net profit of $3.2 billion.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
AstraZeneca's lung cancer therapies Osimertinib and Selumetinib were identified in the context of the Indian National Pharmaceutical Pricing Authority's trade margin rationalization exercise.
AstraZeneca is serving as a Platinum Sponsor for the LUNGevity Foundation's 'Every Breath Forward' initiative, which aims to honor lives and support the lung cancer community.
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.